After early potential, cholesterol medication fenofibrate fails to cut severe symptoms or death in COVID-19 patients
The drug was initially targeted for COVID-19 research as part of an effort to test older, previously approved drugs for potential benefit against the virus. Compared with a placebo, fenofibrate had no significant effect either on severity scores or death from any cause, among other metrics. Researchers say there could be a number of potential explanations for the drug’s failure to achieve the same results in humans that it did in laboratory cells.
FULL STORY AT Penn Medicine News →